How The EHR And New Data Streams Are Influencing Clinical Practice

13 Jun 2018

• By Mark Ratner

A plethora of clinical studies are showing that new types of data, often captured in the EHR, can help improve the correlation between treatments and outcomes and favorably affect patient care as well as enhance drug development.

Mining EHR data to create a more complete picture of the patient • Source: Gayle Rembold Furbert

In many ways, the electronic health record (EHR) remains the central tool for capturing the plethora of new streams of data bubbling through health care. Phenotype measures, patient-reported outcomes (often acquired using digital technology), information on habits and environment, baseline genomic data, claims data and other information increasingly funneled into the EHR are adding to a more complete picture of the patient.

Pharma and hi-tech companies are taking notice: witness recent events such as Apple’s announced intention to make health records portable via its AppleWatch and Roche's blockbuster $1.9 billion acquisition...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

20 May 2025

• By David Wild

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

16 May 2025

• By Jo Shorthouse

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

15 May 2025

• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

13 May 2025

• By David Wild

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

20 May 2025

• By David Wild

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.